Altium Capital is a healthcare investment firm focusing on the development of stage public mid-and small-cap equities.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Altium Capital is a healthcare investment firm focusing on the development of stage public mid-and small-cap equities. It focuses on identifying opportunities to invest in growth companies in the healthcare industry. Founded in 2017 by Jacob Gottlieb, Altium Capital is headquartered in New York.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
12/2020 | Yumanity Therapeutics | Venture Round | 0 |
2/2021 | Hyperfine Research | Series D | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
9/2021 | Renovacor | Post-IPO Equity | 0 |
6/2021 | Ocuphire Pharma | Post-IPO Equity | 15M |
2/2021 | Hyperfine | Series D | 0 |
12/2020 | Palisade Bio | Post-IPO Equity | 22.5M |
3/2021 | EGenesis | Series C | 0 |
2/2021 | Sagimet Biosciences | Venture Round | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
7/2019 | Immutep | Post-IPO Equity | 6.9M |
5/2020 | IMV Inc | Post-IPO Equity | 18M |
2/2022 | Aligned | Seed Round | 0 |
2/2022 | Aligned | Seed Round | 0 |
11/2021 | Antios Therapeutics | Series B | 0 |
9/2021 | Renovacor | Post-IPO Equity | 0 |
6/2021 | Ocuphire Pharma | Post-IPO Equity | 0 |
4/2021 | Antios Therapeutics | Series B | 0 |
3/2021 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
3/2021 | EGenesis | Series C | 0 |
2/2021 | Sagimet Biosciences | Venture Round | 0 |
2/2021 | Hyperfine | Series D | 0 |
2/2021 | Hyperfine Research | Series D | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|